Other languages Xenon Pharmaceuticals Inc.

Equities

XENE

CA98420N1050

Real-time Estimate Cboe BZX Other stock markets 03:31:42 2024-04-29 pm EDT			5-day change	1st Jan Change
42.25 ^USD	+4.32%		+5.42%	-8.42%

Apr. 19	Xenon Pharmaceuticals Inc. Announces Board Resignations	CI
Mar. 11	Transcript : Xenon Pharmaceuticals Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 11:20 AM

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Xenon Pharmaceuticals Inc. Announces Board Resignations	Apr. 19
Xenon Pharmaceuticals Insider Sold Shares Worth $330,290, According to a Recent SEC Filing	Mar. 08
Xenon Pharmaceuticals Insider Sold Shares Worth $601,615, According to a Recent SEC Filing	Mar. 08
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29
Xenon Pharmaceuticals Q4 Net Loss Widens	Feb. 29
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29
Xenon Pharmaceuticals Insider Sold Shares Worth $758,983, According to a Recent SEC Filing	Dec. 15
Sector Update: Health Care Stocks Gain Premarket Thursday	Nov. 30
Xenon Pharmaceuticals Prices $300 Million Public Offering of Common Stock, Pre-Funded Warrants	Nov. 30
Xenon Pharmaceuticals Launches $225 Million Public Offering	Nov. 29
Xenon Pharmaceuticals Says Trial of Depression Drug Failed to Meet Primary Endpoint	Nov. 27
Canada's Xenon Pharma's depression drug fails to meet main goal in study	Nov. 27
Xenon Pharmaceuticals' depression drug fails to meet main goal in study	Nov. 27
Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-Of-Concept X-Nova Clinical Trial of Xen1101 in Major Depressive Disorder	Nov. 27
Sector Update: Health Care Stocks Rising Late Afternoon	Nov. 10
Sector Update: Health Care Stocks Rise Friday Afternoon	Nov. 10
Neurocrine Reports Two Mid-Stage Trial Misses; Shares Fall	Nov. 10
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08
Xenon Pharmaceuticals Announces Publication of Results from Xen1101 Phase 2B "X-Tole" Clinical Trial in Peer-Reviewed Journal Article in Jama Neurology	23-10-09
Xenon Pharmaceuticals Inc. Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress	23-09-04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Xenon Pharmaceuticals Inc.

Equities

XENE

CA98420N1050

Other languages

Filters